U.S. Markets closed

Inhibrx, Inc. (INBX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
22.84+2.78 (+13.86%)
At close: 04:00PM EDT
22.84 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close20.06
Bid21.73 x 900
Ask0.00 x 1000
Day's Range19.39 - 23.29
52 Week Range7.67 - 47.90
Avg. Volume491,169
Market Cap866.892M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.07
Earnings DateMar 10, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.00
  • PR Newswire

    Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance

    Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a robust preclinical pipeline, today announced the completion of Phase 1 dose escalation of INBRX-105, a novel targeted 4-1BB agonist, in combination with Keytruda®. It also reported the funding of an additional $60 million from its Loan and Security Agreement, as amended (the "Loan Agreement"), with Oxford Finance, LLC ("Oxford"), to bring its cash balance to approximately $176 million as of Jun

  • PR Newswire

    Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

    Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that it will be presenting details on the trial design for the INBRX-109 Phase 2 potentially registration-enabling trial in conventional chondrosarcoma at the 2022 American Society of Clinical Oncology ("ASCO") Annual Meeting to be held June 3rd through June 7th, 2022 in Chicago, Illinois.

  • Benzinga

    Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

    Inhibrx Inc (NASDAQ: INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited condition that raises lung and liver disease risks. AAT is a protein that protects the lungs, and the liver makes it. Treatment was well tolerated, with no severe or serious adverse events related to the study drug. Related: Inhibrx Shares Interim Data On INBRX-106 - Keyt